Found: 54
Select item for more details and to access through your institution.
Impact of age on efficacy and toxicity of nilotinib in patients with chronic myeloid leukemia in chronic phase: ENEST1st subanalysis.
- Published in:
- Journal of Cancer Research & Clinical Oncology, 2017, v. 143, n. 8, p. 1585, doi. 10.1007/s00432-017-2402-x
- By:
- Publication type:
- Article
Nilotinib first-line therapy in patients with Philadelphia chromosome-negative/BCR-ABL-positive chronic myeloid leukemia in chronic phase: ENEST1st sub-analysis.
- Published in:
- Journal of Cancer Research & Clinical Oncology, 2017, v. 143, n. 7, p. 1225, doi. 10.1007/s00432-017-2359-9
- By:
- Publication type:
- Article
Next-generation sequencing for BCR-ABL1 kinase domain mutation testing in patients with chronic myeloid leukemia: a position paper.
- Published in:
- Journal of Hematology & Oncology, 2019, v. 12, n. 1, p. N.PAG, doi. 10.1186/s13045-019-0815-5
- By:
- Publication type:
- Article
Psychological well-being and social support in chronic myeloid leukemia patients receiving lifelong targeted therapies.
- Published in:
- 2016
- By:
- Publication type:
- journal article
A Retrospective Analysis about Frequency of Monitoring in Italian Chronic Myeloid Leukemia Patients after Discontinuation.
- Published in:
- Journal of Clinical Medicine, 2020, v. 9, n. 11, p. 3692, doi. 10.3390/jcm9113692
- By:
- Publication type:
- Article
Treatment Recommendations for Chronic Myeloid Leukemia.
- Published in:
- Mediterranean Journal of Hematology & Infectious Diseases, 2014, v. 6, n. 1, p. 1, doi. 10.4084/MJHID.2014.005
- By:
- Publication type:
- Article
Nilotinib: a novel encouraging therapeutic option for chronic myeloid leukemia patients with imatinib resistance or intolerance.
- Published in:
- Biologics: Targets & Therapy, 2007, v. 1, n. 2, p. 121
- By:
- Publication type:
- Article
In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'.
- Published in:
- 2007
- By:
- Publication type:
- Letter
Ponatinib after failure of second‐generation tyrosine kinase inhibitor in resistant chronic‐phase chronic myeloid leukemia.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 11, p. 1419, doi. 10.1002/ajh.26686
- By:
- Publication type:
- Article
First-Line Treatment of Newly Diagnosed Elderly Patients with Chronic Myeloid Leukemia: Current and Emerging Strategies.
- Published in:
- 2014
- By:
- Publication type:
- Journal Article
14-3-3 Binding and Sumoylation Concur to the Down-Modulation of β-catenin Antagonist chibby 1 in Chronic Myeloid Leukemia.
- Published in:
- PLoS ONE, 2015, v. 10, n. 7, p. 1, doi. 10.1371/journal.pone.0131074
- By:
- Publication type:
- Article
Efficacy and safety of nilotinib as frontline treatment in elderly (> 65 years) chronic myeloid leukemia patients outside clinical trials.
- Published in:
- Annals of Hematology, 2023, v. 102, n. 6, p. 1375, doi. 10.1007/s00277-023-05159-9
- By:
- Publication type:
- Article
Identification, prevention and management of cardiovascular risk in chronic myeloid leukaemia patients candidate to ponatinib: an expert opinion.
- Published in:
- 2017
- By:
- Publication type:
- journal article
A review of the European LeukemiaNet recommendations for the management of CML.
- Published in:
- Annals of Hematology, 2015, v. 94, p. 141, doi. 10.1007/s00277-015-2322-2
- By:
- Publication type:
- Article
Impact of BCR-ABL mutations on response to dasatinib after imatinib failure in elderly patients with chronic-phase chronic myeloid leukemia.
- Published in:
- Annals of Hematology, 2013, v. 92, n. 2, p. 179, doi. 10.1007/s00277-012-1591-2
- By:
- Publication type:
- Article
Physicians' attitude towards selection of second line therapy with nilotinib and dasatinib in chronic myeloid leukemia patients.
- Published in:
- 2017
- By:
- Publication type:
- Letter
In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Droplet Digital PCR for BCR–ABL1 Monitoring in Diagnostic Routine: Ready to Start?
- Published in:
- Cancers, 2021, v. 13, n. 21, p. 5470, doi. 10.3390/cancers13215470
- By:
- Publication type:
- Article
Molecular response and quality of life in chronic myeloid leukemia patients treated with intermittent TKIs: First interim analysis of OPTkIMA study.
- Published in:
- Cancer Medicine, 2021, v. 10, n. 5, p. 1726, doi. 10.1002/cam4.3778
- By:
- Publication type:
- Article
Perspectives and Emotional Experiences of Patients With Chronic Myeloid Leukemia During ENESTPath Clinical Trial and Treatment-Free Remission: Rationale and Protocol of the Italian Substudy.
- Published in:
- Frontiers in Oncology, 2021, v. 11, p. 1, doi. 10.3389/fonc.2021.638689
- By:
- Publication type:
- Article
Dosing Strategies for Improving the Risk-Benefit Profile of Ponatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase.
- Published in:
- Frontiers in Oncology, 2021, v. 11, p. N.PAG, doi. 10.3389/fonc.2021.642005
- By:
- Publication type:
- Article
First-line treatment of chronic myeloid leukemia with nilotinib: critical evaluation.
- Published in:
- Journal of Blood Medicine, 2012, v. 3, p. 151, doi. 10.2147/JBM.S13067
- By:
- Publication type:
- Article
Nilotinib: A Viewpoint by Gianantonio Rosti.
- Published in:
- Drugs, 2008, v. 68, n. 4, p. 460, doi. 10.2165/00003495-200868040-00006
- By:
- Publication type:
- Article
A case of coexistence between JAK2V617F and BCR /ABL.
- Published in:
- 2008
- By:
- Publication type:
- Letter
FOXM1 Transcription Factor: A New Component of Chronic Myeloid Leukemia Stem Cell Proliferation Advantage.
- Published in:
- Journal of Cellular Biochemistry, 2017, v. 118, n. 11, p. 3968, doi. 10.1002/jcb.26052
- By:
- Publication type:
- Article
The Italian Multicentric Randomized OPTkIMA Trial on Fixed vs Progressive Intermittent TKI Therapy in CML Elderly Patients: 3-Years of Molecular Response and Quality of Life Monitoring After Completing the Treatment Plan.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2024, v. 24, n. 5, p. 323, doi. 10.1016/j.clml.2024.01.008
- By:
- Publication type:
- Article
CML-182: SETD2 Loss of Function Induces Genomic Instability in CML and May Contribute to Disease Progression to Blast Crisis.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S329, doi. 10.1016/S2152-2650(21)01772-9
- By:
- Publication type:
- Article
CML-129: OPTIC Primary Analysis: A Dose-Optimization Study of 3 Starting Doses of Ponatinib (PON).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S328, doi. 10.1016/S2152-2650(21)01769-9
- By:
- Publication type:
- Article
Poster: CML-182: SETD2 Loss of Function Induces Genomic Instability in CML and May Contribute to Disease Progression to Blast Crisis.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S225, doi. 10.1016/S2152-2650(21)01419-1
- By:
- Publication type:
- Article
Poster: CML-129: OPTIC Primary Analysis: A Dose-Optimization Study of 3 Starting Doses of Ponatinib (PON).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S223, doi. 10.1016/S2152-2650(21)01408-7
- By:
- Publication type:
- Article
Oral Abstract: CML-129: OPTIC Primary Analysis: A Dose-Optimization Study of 3 Starting Doses of Ponatinib (PON).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S202, doi. 10.1016/S2152-2650(21)01274-X
- By:
- Publication type:
- Article
Outcome of Imatinib Treatment in Yemeni Patients With Chronic Myeloid Leukemia and the Influence of Nonadherence to Treatment and Duration of Previous Hydroxyurea Therapy.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Primary Results of the Phase 4 BYOND Study of Bosutinib for Pretreated Chronic Phase (CP) Chronic Myeloid Leukemia (CML).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. S290, doi. 10.1016/j.clml.2019.07.235
- By:
- Publication type:
- Article
Autologous bone marrow transplantation with immunotoxin-purged marrow for advanced multiple myeloma.
- Published in:
- European Journal of Haematology, 1989, v. 43, n. S51, p. 176, doi. 10.1111/j.1600-0609.1989.tb01513.x
- By:
- Publication type:
- Article
High-dose chemoradiotherapy and allogeneic bone marrow transplantation in multiple myeloma.
- Published in:
- European Journal of Haematology, 1989, v. 43, n. S51, p. 191, doi. 10.1111/j.1600-0609.1989.tb01516.x
- By:
- Publication type:
- Article
High-dose therapy followed by autologous bone marrow transplantation (ABMT) in previously untreated non-Hodgkin's lymphoma.
- Published in:
- European Journal of Haematology, 1986, v. 37, n. 4, p. 347, doi. 10.1111/j.1600-0609.1986.tb02325.x
- By:
- Publication type:
- Article
Developmental Therapeutics Consortium report on study design effects on trial outcomes in chronic myeloid leukaemia.
- Published in:
- European Journal of Clinical Investigation, 2012, v. 42, n. 9, p. 1016, doi. 10.1111/j.1365-2362.2012.02675.x
- By:
- Publication type:
- Article
Ciclosporin A: Correlation of Blood Levels with Acute Graft-versus-Host Disease after Bone Marrow Transplantation.
- Published in:
- Acta Haematologica, 1987, v. 78, n. 1, p. 6, doi. 10.1159/000205827
- By:
- Publication type:
- Article
Safety profile of bosutinib in Japanese versus non-Japanese patients with chronic myeloid leukemia: a pooled analysis.
- Published in:
- International Journal of Hematology, 2022, v. 115, n. 6, p. 838, doi. 10.1007/s12185-022-03314-y
- By:
- Publication type:
- Article
Ponatinib treatment in chronic myeloid leukemia cell lines targets aurora kinase A/FOXM1 axis.
- Published in:
- 2020
- By:
- Publication type:
- Letter
Prognosis in Chronic Myeloid Leukemia: Baseline Factors, Dynamic Risk Assessment and Novel Insights.
- Published in:
- Cells (2073-4409), 2023, v. 12, n. 13, p. 1703, doi. 10.3390/cells12131703
- By:
- Publication type:
- Article
Making Treatment-Free Remission (TFR) Easier in Chronic Myeloid Leukemia: Fact-Checking and Practical Management Tools.
- Published in:
- Targeted Oncology, 2021, v. 16, n. 6, p. 823, doi. 10.1007/s11523-021-00831-4
- By:
- Publication type:
- Article
Evaluation of residual CD34<sup>+</sup>Ph<sup>+</sup> progenitor cells in chronic myeloid leukemia patients who have complete cytogenetic response during first-line nilotinib therapy.
- Published in:
- Cancer (0008543X), 2012, v. 118, n. 21, p. 5265, doi. 10.1002/cncr.27506
- By:
- Publication type:
- Article
Testing Sokal's and the new prognostic score for chronic myeloid leukaemia treated with α-interferon.
- Published in:
- British Journal of Haematology, 2000, v. 111, n. 2, p. 587
- By:
- Publication type:
- Article
Second chronic phase before transplantation is crucial for improving survival of blastic phase chronic myeloid leukaemia.
- Published in:
- British Journal of Haematology, 2000, v. 109, n. 4, p. 722, doi. 10.1046/j.1365-2141.2000.02060.x
- By:
- Publication type:
- Article
Choosing the Best Second-Line Tyrosine Kinase Inhibitor in Imatinib- Resistant Chronic Myeloid Leukemia Patients Harboring Bcr-Abl Kinase Domain Mutations: How Reliable Is the IC<sub>50</sub>?
- Published in:
- Oncologist, 2011, v. 16, n. 6, p. 868, doi. 10.1634/theoncologist.2010-0388
- By:
- Publication type:
- Article
Consistency matters: measurement invariance of the EORTC QLQ-C30 questionnaire in patients with hematologic malignancies.
- Published in:
- 2020
- By:
- Publication type:
- Journal Article
Polo-like kinase-1, Aurora kinase A and WEE1 kinase are promising druggable targets in CML cells displaying BCR::ABL1-independent resistance to tyrosine kinase inhibitors.
- Published in:
- Frontiers in Oncology, 2022, v. 12, p. 1, doi. 10.3389/fonc.2022.901132
- By:
- Publication type:
- Article
Combined Use of Growth Factors to Stimulate the Proliferation of Hematopoietic Progenitor Cells after Autologous Bone Marrow Transplantation for Lymphoma Patients.
- Published in:
- Acta Haematologica, 1996, v. 95, n. 3/4, p. 164, doi. 10.1159/000203872
- By:
- Publication type:
- Article
Patient‐reported symptom monitoring and adherence to therapy in patients with newly diagnosed chronic myeloid leukemia.
- Published in:
- Cancer (0008543X), 2024, v. 130, n. 2, p. 287, doi. 10.1002/cncr.35021
- By:
- Publication type:
- Article